Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases
Tóm tắt
Fifteen years have passed since the first description of interleukin (IL)-8/CXCL8 as a potent neutrophil chemotactic factor. Accumulating evidence has demonstrated that various types of cells can produce a large amount of IL-8/CXCL8 in response to a wide variety of stimuli, including proinflammatory cytokines, microbes and their products, and environmental changes such as hypoxia, reperfusion, and hyperoxia. Numerous observations have established IL-8/CXCL8 as a key mediator in neutrophil-mediated acute inflammation due to its potent actions on neutrophils. However, several lines of evidence indicate that IL-8/CXCL8 has a wide range of actions on various types of cells, including lymphocytes, monocytes, endothelial cells, and fibroblasts, besides neutrophils. The discovery of these biological functions suggests that IL-8/CXCL8 has crucial roles in various pathological conditions such as chronic inflammation and cancer. Here, an overview of its protein structure, mechanisms of production, and receptor system will be discussed as well as the pathophysiological roles of IL-8/CXCL8 in various types of lung pathologies.
Từ khóa
Tài liệu tham khảo
Bacon KB, 1994, Immunology, 82, 473
Bellocq A, 1998, Am J Pathol, 152, 83
Belperio JA, 2000, J Leukoc Biol, 68, 1
Broaddus VC, 1994, J Immunol, 152, 2960
Burger M, 1999, J Immunol, 163, 2017
Burns AR, 1996, J Immunol, 156, 3389
Chuntharapai A, 1994, J Immunol, 155, 2587
Chuntharapai A, 1994, J Immunol, 153, 5682
Djeu JY, 1990, J Immunol, 144, 2205
Friedl HP, 1990, Am J Pathol, 136, 491
Hebert CA, 1990, J Immunol, 145, 3033
Jinquan T, 1997, J Immunol, 158, 475
Keane MP, 1997, J Immunol, 159, 1437
Keane MP, 1999, J Immunol, 163, 5686
Keane MP, 1999, J Immunol, 162, 5511
Kitadai Y, 2000, Clin Cancer Res, 6, 2735
Kitadai Y, 1998, Am J Pathol, 152, 93
Kudo C, 1991, J Immunol, 147, 2196
Kuna P, 1991, J Immunol, 147, 1920
Matsumoto T, 1997, Lab Invest, 77, 119
McCord JM., 1987, Fed Proc, 46, 2402
Mori N, 1998, Cancer Res, 58, 3993
Mukaida N., 2000, Int J Hematol, 72, 391
Mul FP, 2000, J Leukoc Biol, 68, 529
Murphy PM, 2000, Pharmacol Rev, 52, 145
Paolini JF, 1994, J Immunol, 153, 2704
Schroder JM, 1987, J Immunol, 139, 3473
Takizawa H, 1999, J Immunol, 162, 4705
Tsai WC, 1998, J Immunol, 161, 2435
Van Zee KJ, 1991, J Immunol, 146, 3478
Xu L, 1999, Cancer Res, 59, 5822
Yokoi K, 1997, Lab Invest, 76, 375